ACT 1014 6470
Alternative Names: ACT-1014-6470Latest Information Update: 28 Dec 2024
At a glance
- Originator Idorsia Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement C5a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers, In adults) in Czech Republic (PO, Capsule)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in Germany (PO, Capsule)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in Netherlands (PO, Capsule)